Leverage The Bracken Group’s integrated, multi-discipline life sciences consulting team to expertly engage in the process of entertaining deals and alliances.
Protect and defend your position. Leverage the knowledge and experience of The Bracken Group
Bracken experts in due diligence
Andrew L. Salzman, MD
Andy is a physician, scientist, entrepreneur, executive, and pharmaceutical development specialist who has founded and led multiple biotechnology companies, several of which have been subjected to, and survived, due diligence inquiries. Additionally, in the course of his career he has vetted approximately 300 companies and their products and assets.
Victor Miranda, MD, MBA
A physician and leader in the field of medical device development, Victor most recently served as Chief Medical Officer for 3M, a position that he originated. He has had extensive experience at the executive level in both domestic and international business with companies that include GE Healthcare and Johnson & Johnson.
Colin G. Miller, PhD, FIPEM, CSci
Co-founder and managing partner of Bracken, Colin served as Senior Vice President of Medical Affairs at BioClinica where he was instrumental in formulating company strategy and evaluating potential targets for acquisition. His due diligence experience also includes in-depth review of company assets and analysis of companies in the pharmaceutical services sector.
Jim Gilligan, PhD, MSIB
Jim is a scientist, entrepreneur, and executive who has co-founded and helped to lead multiple biopharma and biotech companies, including Tarsa Therapeutics, Herborium Inc., and Unigene Labs. His extensive background in drug development provides a sound foundation for savvy assessment of the scientific and clinical rationale and viability for products/technologies under development. His international business experience informs his ability to analyze competitive landscapes and defend corporate/product valuations.
Brad Wyman, PhD
Brad has more than 20 years of experience working with startups and small companies. His career includes serving as vice president of Imaging and Clinical Development at ImaginAB, and, for ten years, serving as head of Functional and Structural Neuroimaging at Pfizer, where he worked with vendors to ensure they had the operational and financial stability to deliver. He has conducted multiple due diligence exercises and in one case, his analysis led to spinning out technology from a university to a new company.
Nick Spring, DipM, BSc (Hons)
Nick is a highly experienced executive with a track record of team building, strategic planning, and tactical execution in medical devices, pharma, and biotech. He has held leadership positions with Smith & Nephew, Merck, and Merial, among others. In 2020, Nick served as founding CEO of ViralClear Pharmaceuticals, a company working on a treatment for COVID-19. Nick’s extensive work in due diligence includes large and small pharma, biotech, and med device companies in the US and globally.
Lieselotte Bloss, DV
A co-founder of Bracken, Liz has held positions at Sanofi, Novo Nordisk, Bracco, Kyowa Hakko Kirin, and Taiho Oncology. She is an accomplished drug development strategist and a seasoned regulatory leader with a strong track record of delivering IND, NDA, and MAA submissions in multiple therapeutic areas. Her work in due diligence has focused on regulatory gap analyses—assessing the potential for client assets to pass the key regulatory hurdles required to get to market.